1Garcia JS’Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndrome[J]. Onco Targets Ther,2010,3(1):1-13.
2Valent P,Horny HP’Bennett JM,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference[J]. Leuk Res, 2007,31 ?6):727-736.
3Vardiman JW,Thiele J, Arber DA,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and a-cute leukemia : rationale and important changes[J]. Blood,2009,114(5): 937 - 951.
4Dykes JH,Lindmark A,Lenhoff S,et al. Autologous del (20q)-positive erythroid progenitor cells,re-emerging after DLI treatment of an MDS patient relapsing after alio-SCT,can provide a normal peripheral red blood cell count[J]. Bone Marrow Transplantation,2004,33(5) :559-563.
5Saitoh K, Miura I,Takahashi N ,et al. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes[J]. Blood, 1998,92(8),2886-2892.
6Nilsson L,Astrand-Grundstrom I,Arvidsson I,et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q -deleted myelodysplastic syndromes : evidence for involvement at the hematopoietic stem cell level[J]. Blood, 2000,96 (6) : 2012-2021.
